Cingulate Inc. Operating Lease, Liability, Current
Cingulate Inc. (CING) had Operating Lease, Liability, Current of $255.13 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-13
- 2026-06-30: Operating Lease, Liability, Current $255.13K.
- 2026-03-31: Operating Lease, Liability, Current $246.86K.
- 2025-12-31: Operating Lease, Liability, Current $238.86K.
- 2025-09-30: Operating Lease, Liability, Current $231.12K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $255.13K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $246.86K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $238.86K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $231.12K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $223.63K 10-Q · filed 2025-08-19 |
| 2025-03-31 | $33.15K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $130.66K 10-K · filed 2026-03-18 |
| 2024-09-30 | $225.37K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $317.34K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $372.34K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $358.08K 10-K · filed 2025-03-27 |
| 2023-09-30 | $353.18K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $348.50K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $344.03K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $339.75K 10-K · filed 2024-04-01 |
| 2021-12-31 | $295.60K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |